Cancer Targeted Treatment: From Molecule to Infusion

Includes a Live Web Event on 06/03/2025 at 1:00 PM (EDT)

This session will provide participants with an overview of new and unique targeted treatments for cancer, including mechanism of action, administration guidelines, and toxicity management. The presenter will use a case-based approach to reinforce the pathophysiology of driver mutations. 

Learning Objectives: At the conclusion of this session, learners will be able to: 
• Describe the drivers for cancer development
• List 4 targets for cancer treatment
• Outline the side effects of targeted cancer treatments

Christine Rimkus, APRN, MSN, AOCN

Christine Rimkus, APRN, MSN, AOCN, has been an oncology nurse for 39 years.  She graduated from Southern Illinois University  Edwardsville with her BSN and then, in 1992, obtained her master’s in nursing with a focus in oncology from St. Louis University.  Her oncology experience spans the practice spectrum, including inpatient, outpatient, and home infusion. She has cared for a range of cancer patients, from surgical oncology, outpatient infusion, radiation oncology, and stem cell transplant. Ms Rimkus has been a nurse educator and consultant, offering lectures and clinical consultation to both health care professionals and patient/caregiver groups. She has authored and coauthored numerous publications in oncology journals and textbooks. Currently, she works as an advanced practice provider at St. Louis University.

CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

Contact Hours: This session has been approved for 1 contact hour

Expiration date for receipt of contact hours: June 3, 2028

To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

Key:

Complete
Failed
Available
Locked
Cancer Targeted Treatment: From Molecule to Infusion
Live event: 06/03/2025 at 1:00 PM (EDT) You must register to access.
Webinar Evaluation